RecruitingNot ApplicableNCT05581745

A2 to O Lung Transplants

Blood Group A2 Donor to Blood Group O Recipient Lung Transplantation


Sponsor

University Health Network, Toronto

Enrollment

10 participants

Start Date

Jul 14, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • first lung transplant
  • blood group O recipient
  • low pre-operative anti-A antibody titers
  • consent to study participation

Exclusion Criteria3

  • re-transplant
  • multiorgan transplant
  • positive virtual crossmatch at time of transplant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBlood group A2 donor to blood group O recipient lung transplant surgery

Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant


Locations(1)

Toronto General Hospital, University Health Network

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05581745


Related Trials